NeuPath Health (TSXV:NPTH) Marketable Securities: C$0.00 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSXV:NPTH NeuPath Health Inc TSXV:NPTH
39 GF Score
Price C$0.55
GF Value C$0.25
Valuation Significantly Overvalued
! 2 Warning Signs
View Full Analysis

What is NeuPath Health Marketable Securities?

NeuPath Health TSXV:NPTH 39 Marketable Securities is C$0.00 Mil as of Jun. 2026. GuruFocus rates TSXV:NPTH with a GF Score™ of 39/100 and a GF Value™ of C$0.25 (Significantly Overvalued). The stock has 2 warning signs investors should review.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price. NeuPath Health's Marketable Securities for the quarter that ended in Jun. 2026 was C$0.00 Mil.

NeuPath Health  (TSXV:NPTH) Marketable Securities Explanation

Marketable Securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

Please note, GuruFocus' Marketable Securities also includes "Other Short Term Investment".

NeuPath Health Marketable Securities Related Terms

NeuPath Health Marketable Securities Historical Data

* Premium members only.

The historical data trend for NeuPath Health's Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

NeuPath Health Marketable Securities Chart

NeuPath Health Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Marketable Securities
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

NeuPath Health Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Marketable Securities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
TSXV:NPTH
39GF Score
NeuPath Health Inc TSXV:NPTH
Marketable Securities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

NeuPath Health Marketable Securities Calculation

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Frequently Asked Questions Learn more about Marketable Securities →
What does a Marketable Securities of C$0.00 Mil mean?
NeuPath Health (TSXV:NPTH) has a Marketable Securities of C$0.00 Mil as of Jun. 2026. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on NeuPath Health and its competitors.
Is NeuPath Health's Marketable Securities too high?
NeuPath Health's current Marketable Securities is C$0.00 Mil. Overall, NeuPath Health has a GF Score™ of 39/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does NeuPath Health's Marketable Securities compare to HCA and THC?
NeuPath Health's Marketable Securities of C$0.00 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Marketable Securities for a Healthcare Providers & Services company?
A good Marketable Securities depends on the Healthcare Providers & Services industry context. However, Marketable Securities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Marketable Securities mean?
A high Marketable Securities can signal that a stock is expensive relative to its fundamentals. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on NeuPath Health and its competitors. NeuPath Health's current Marketable Securities is C$0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NeuPath Health stock overvalued right now?
Based on GuruFocus' analysis, NeuPath Health (TSXV:NPTH) is currently considered Significantly Overvalued. The stock's GF Value™ is C$0.25, compared to a current price of C$0.55 — trading 120% above its estimated fair value. The current Marketable Securities is C$0.00 Mil. NeuPath Health's overall GF Score™ is 39/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Marketable Securities calculated?
Marketable Securities is calculated from a company's financial statements. For NeuPath Health (TSXV:NPTH), the current Marketable Securities is C$0.00 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is NeuPath Health (TSXV:NPTH) Overvalued in 2026?

Based on GuruFocus' analysis, NeuPath Health stock appears to be overvalued. The current stock price of C$0.55 is trading 120% above its estimated GF Value™ of C$0.25. GuruFocus considers NeuPath Health to be Significantly Overvalued.

Key valuation signals for TSXV:NPTH:

  • Marketable Securities: C$0.00 Mil
  • GF Value™: C$0.25 vs. price of C$0.55 (120% above fair value)
  • GF Score™: 39/100 with 2 warning signs

No single metric tells the full story. See the TSXV:NPTH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

NeuPath Health Business Description

Address 181 Bay Street, Suite 2100, Toronto, ON, CAN, M5J 2T3
NeuPath Health Inc operates an end-to-end, integrated network of healthcare businesses. It utilizes research, data-driven insights, technology, and interdisciplinary care to help restore function for patients impacted by acute and chronic musculoskeletal conditions, including chronic pain, spinal injuries, sports-related injuries, and concussions. It operates an interdisciplinary network of medical clinics in Ontario and Alberta, in addition to an independent medical assessment business with a national network of healthcare providers. Its medical clinics provide comprehensive assessments and rehabilitation services to clients with chronic pain, musculoskeletal or back injuries, sports-related injuries, and concussions. The company operates in one industry segment: medical services.
39GF Score

Get the complete analysis for TSXV:NPTH

Marketable Securities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

C$0.55
Price
C$0.25
GF Value